GT Medical Technologies develops GammaTile, an FDA-cleared bioresorbable radiation-emitting implant placed at the time of brain tumor resection to deliver immediate, localized radiation to the surgical bed. The company highlights pivotal ROADS Phase 3 randomized controlled trial results presented at ASCO 2026 showing a 12-month surgical bed recurrence rate of 1.3% with GammaTile versus 15.4% with standard of care and improved survival outcomes. GT recently initiated the BRIDGES randomized controlled trial in newly diagnosed glioblastoma patients and plans to use proceeds from its Series E financing to expand that trial and scale commercial and operational efforts. The company was founded by a team of tumor specialists and announced the Series E from Tempe, Arizona. GT positions GammaTile as eliminating the delay between surgery and postoperative radiation by delivering immediate treatment at the resection site. The firm states the clinical data and new financing support its goal of broader adoption and further clinical development.

Total raised

$243M

Funding rounds

6

Latest round

Series E

Latest activity

Jun 2026